SweetValueLab
Write for us

MetLife, Inc. — Intrinsic Value & Fair Price

MET
NYSEFinancial ServicesInsurance - LifeCIK 0001099219metlife.comAbout MET
Last close · Oct 16, 2026100.76+0.49 (+0.49%)
Market cap$64.0B
Model value · P/B · justified
47.43
MetLife closed at $100.76 — overvalued by 112% vs model.
41.50the model's range55.33

P/B · justified leads for an insurer. From the justified price to book.

Other models
46.03 – 255.73
Wall St. target
110.00 8% below
Above model, 1y
20 of 20 days

Price and model value

Embed this card

MET's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Dividends

Quarterly · as of Oct 16, 2026
Yield, trailing 12 months
2.30%
Past 2 years
low 2.30%high 3.35%
Today is at its 2-year low.
Dividends per share, a year at a time
$1.88Aug ’21$1.96Aug ’22$2.04Aug ’23$2.13Aug ’24$2.23Aug ’25$2.32TTM
Dividends / earnings, FY2025
44.7%
Raised
12 years in a row
Growth, 5 yrs
4.3% a year
Last change
+4.4% · May 2026
Every payment, with ex-dates · latest $0.5925, paid Sep 8, 2026

Research on MET

No posts on MET yet.
Studied MET from its filings? Guest posts are reviewed before they go live.Write about MET →

How it is valued

Valued asInsurer
Low/slowing growth (~5% recent)High profitability (139% net margin)Pays dividendsHighly cyclical earnings
What growth the price implies: the reverse DCF

Key figures

FY2025 · chosen for insurers
Price / book
2.3×
Return on equity
11.9%
P/E
21.4×
Dividend yield, TTM
2.30%
Payout ratio
50.4%
Debt / equity
0.7
Full financials

Analyst actions

third-party, quoted
10-07Barclays · target111.00
10-07Mizuho Securities · target109.00
10-06UBS · target110.00
09-22Piper Sandler · “Overweight” from “Neutral”upgrade
Ratings, targets and estimates

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just MET. No account.

About MetLife

MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S., Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its broad insurance offerings include life, dental, group short-term and long-term disability, individual disability, pet, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans. MetLife also supports employers with administrative services-only (ASO) arrangements. Furthermore, it provides sophisticated financial instruments such as general and separate account contracts, synthetic guaranteed interest contracts, and private floating rate funding agreements. The company facilitates pension risk transfers, offers institutional income annuities, structures settlements, and delivers capital markets investment products. Specialized life insurance products and funding agreements are also available for post-retirement benefits, alongside company, bank, or trust-owned life insurance used to finance non-qualified executive benefit programs. In addition, MetLife offers a variety of annuity options including fixed, indexed-linked, and variable, alongside pension and regular savings products. Its life insurance portfolio features whole life, term life, endowments, universal and variable life, and group life policies. The company also provides longevity reinsurance solutions, credit insurance products, and protection for long-term healthcare services. MetLife, Inc. was founded in 1863 and is headquartered in New York City.

CEO
Michel Abbas Khalaf
Headquarters
New York City, NY
Employees
46,000
IPO
2000-04-05
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.